Functional cure rates were significantly higher with bepirovirsen plus standard of care [i.e. nuke therapy] compared with standard of care alone.
Functional cure for CHB is when the virus can no longer be detected in the blood as measured by the sustained loss of hepatitis B surface antigen (HBsAg), a viral protein that signals ongoing infection, and undetectable hepatitis B virus DNA for at least 24 weeks after a finite course of treatment.
The data will be presented at an unspecified medical conference.